Back to search

Article

Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19

2021-09-21

Abstract excerpt

<h4>ABSTRACT</h4> Robust polyclonal humoral immune responses have the potential to generate a diverse set of antibodies to neutralize and eliminate viruses such as SARS-CoV-2 and protect against transmission, re-infection and the evolution of variants that evade immunity. CD73 is present on subsets of human B and T cells where it plays a role in lymphocyte activation and migration. CD73 also functions as an ectoen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ac3e4fcd-751b-5b11-a617-ccf185165da3
DOI
10.1101/2021.09.13.21263406
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19DOI 10.1101/2021.09.13.21263406
Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19Semantic proximity
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialSemantic proximity
Deep profiling of antigen-specific B cells from different pathogens identifies novel compartments in the IgG memory B cell and antibody-secreting cell lineagesSemantic proximity
The efficacy and safety of monoclonal antibody treatments against COVID-19: A systematic review and meta-analysis of randomized clinical trialsSemantic proximity
SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients.Semantic proximity
COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic reviewSemantic proximity
Human naïve B cells show evidence of anergy and clonal redemption following vaccinationSemantic proximity
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiencySemantic proximity
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical TrialSemantic proximity
A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery.Semantic proximity
Chemokine Receptor Inhibitor vMIP-II Promoting Lymphocytes in COVID-19 Patients and Its Related Mechanism In VitroSemantic proximity
Chemokine Receptor Inhibitor vMIP-II Promoting Lymphocytes in COVID-19 Patients and Its Related Mechanism In VitroSemantic proximity
Select a neighboring publication to make it the new centre.